Company Announcement

CLINUVEL TO TAKE 100% OWNERSHIP OF VALLAURIX

Full control to be taken of subsidiary focused on novel R&D and new product development

- CLINUVEL Group to acquire 18% of Singaporean joint venture VALLAURIX PTE LTD from Biotech Lab Singapore Pte Ltd for 33,559 CLINUVEL ordinary shares
- VALLAURIX PTE LTD will continue to focus on R&D
- CLINUVEL to expand its research facilities in Singapore

Melbourne, Australia, 01 May 2018

CLINUVEL PHARMACEUTICALS LTD **(ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION: CLVLY)** today announced that it has entered into an agreement to acquire 18% of the joint venture established in 2014 between CLINUVEL and Biotech Lab Singapore Pte Ltd (BLS). With this transaction CLINUVEL will gain 100% ownership of VALLAURIX in Singapore.

CLINUVEL will issue 33,559 ordinary shares of CLINUVEL (ASX: CUV) representing an implied value (based on the one-month volume weighted average price of CLINUVEL shares as of 27 April 2018) of SGD$10.727 per CLINUVEL share, equating to a total of SGD$360,000 for the 18% equity stake currently held by BLS in VALLAURIX. All VALLAURIX staff will be retained following the acquisition.

VALLAURIX was established in 2014 to diversify the CLINUVEL Group's in-house work and develop topical products complementary to CLINUVEL's lead pharmaceutical product, SCENESSE® (afamelanotide 16mg). The joint venture aimed to exploit CLINUVEL's scientific expertise in melanocortins in combination with the operational oversight of a local partner, allowing for a proportionate sharing of financial risks along with potential commercial upside. SCENESSE® is the world's first systemic photoprotective therapy prescribed to adult patients diagnosed with erythropoietic protoporphyria (EPP), and the first ever melanocortin receptor 1 (MC1R) agonist approved by regulatory authorities.[1]

CLINUVEL continues to invest in its R&D operations in Singapore with a view to further expand and develop its portfolio of products, particularly focussing on the family of melanocortins to which SCENESSE® belongs. The Company is in the process of expanding its laboratory facilities to support R&D work. The integration of VALLAURIX with CLINUVEL's South-East Asian operations brings it in line with all other Group subsidiaries which are wholly-owned by the Australian parent entity, CLINUVEL PHARMACEUTICALS LTD.

COMMENTARY

"Today's value of CLINUVEL is largely based on the successful development, approval, and commercialisation of SCENESSE®," CLINUVEL's Chief Financial Officer, Darren Keamy said. "This would not have been possible without the persistence and expert knowledge of the entire CLINUVEL team. Expanding our facilities and developing new products seeks to leverage this expertise and allows us to expand further."

"We will have all of CLINUVEL's Singaporean activities under one roof, resulting in a simplified business structure. By leveraging the Company's knowledge base across its global offices, the purchase of the minority interest in VALLAURIX allows the Group to have full operational and financial control of its global activities. The existing senior management of VALLAURIX will remain, allowing us to retain regional knowledge and continuity of business, and preserve important Company knowhow. We intend to be one of the few integrated pharmaceutical companies with a development hub out of Singapore to develop first-in-class pharmaceutical and over-the-counter products," Mr Keamy said.

– End –

[1] SCENESSE® (afamelanotide 16mg) is approved in Europe as an orphan medicinal product for the prevention of phototoxicity in adult patients with EPP. Information on the product can be found on CLINUVEL's website at www.clinuvel.com.

About CLINUVEL PHARMACEUTICALS LIMITED
CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders. As pioneers in photomedicine and understanding the interaction of light and human biology, CLINUVEL's research and development has led to innovative treatments for patient populations with a clinical need for photoprotection and repigmentation. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL's lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at http://www.epp.care.
Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Switzerland, the US and Singapore.
For more information go to http://www.clinuvel.com.

Media enquiries
Lachlan Hay, CLINUVEL (UK) LTD. +44 1372 860 765 Lachlan.Hay@clinuvel.com

Investor enquiries
InvestorRelations@clinuvel.com

Forward-Looking Statements
This release to the Australian Securities Exchange and to press may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause CLINUVEL's actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that the FDA may require additional studies beyond the studies planned for product candidates or may not provide regulatory clearances, including for SCENESSE®; that the FDA may not provide regulatory approval for any use of SCENESSE® or that the approval may be limited; that CLINUVEL may never file an NDA for SCENESSE® regulatory approval in the US; that the Company may not be able to access adequate capital to advance its vitiligo programs; that the Company may not be able to retain its current pharmaceutical and biotechnology key personnel and knowhow for further development of its product candidates or may not reach favourable agreements with potential pricing and reimbursement agencies in Europe and the US.

Level 6, 15 Queen Street T +61 3 9660 4900 www.clinuvel.com
Melbourne, Victoria 3000 F +61 3 9660 4999
Australia